Mesoblast Limited (ASX:MSB) revealed that the Company commenced enrollment for a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether remestemcel-L (allogeneic mesenchymal stem cell therapy) provides a survival benefit in moderate/severe acute respiratory distress syndrome (ARDS) due to COVID-19.
Mesoblast unveiled that more than 20 medical centers across the US shall take part in the trial, and it is projected to complete enrollment within 3-4 months.
Shares of MSB climbed 4.1% to $3.290 on 30 April 2020 (at AEST 11:42 AM)